Literature DB >> 1671776

Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis.

P O'Hanley1, G Lalonde, G Ji.   

Abstract

Digalactoside-binding (Gal-Gal) pili and alpha-hemolysin of Escherichia coli have been implicated as important virulence determinants in the pathogenesis of human ascending, nonobstructive pyelonephritis. The pathogenic significance of these determinants was evaluated in vitro and in the BALB/c mouse pyelonephritis model by employing wild-type, avirulent laboratory, and genetically defined cosmids, transformants, and recombinant strains. In vitro data suggest that the cytolytic activity of hemolysin is significantly (P less than 0.05) enhanced among digalactoside-binding strains which agglutinate erythrocytes. The basis of increased hemolysis is related presumably to more efficient delivery of the toxin to target lipid substrate in the host plasma membrane. Intravesicular administration of bacteria that express both digalactoside binding and hemolysin generally resulted in greater mortality and renal parenchymal injury in mice than strains that expressed none or only one of these determinants. Analyses convincingly demonstrate that digalactoside-binding pili are correlated with upper urinary tract colonization and that hemolysin is correlated with septicemia and renal parenchymal damage. These determinants collectively constitute the minimal virulence factors to produce disease in this model. Their efficacy as vaccines for the prevention of pyelonephritis was also assessed. A purified Gal-Gal pilus vaccine prevented (P less than 0.05) subsequent colonization by a challenge wild-type strain that exhibited homologous pili. The hemolysin vaccine did not abrogate subsequent bacterial renal colonization on challenge, but it did protect (P less than 0.05) mice which survived challenge from subsequent renal injury compared with those in the saline control group. The combination of these determinants was also protective. The combination of Gal-Gal pili and hemolysin in a vaccine preparation represents a potentially worthwhile strategy for human immunoprophylaxis against pyelonephritis by interdicting several steps in the pathogenesis of a bacterial mucosal infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671776      PMCID: PMC258381          DOI: 10.1128/iai.59.3.1153-1161.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

1.  A highly sensitive silver stain for detecting proteins and peptides in polyacrylamide gels.

Authors:  R C Switzer; C R Merril; S Shifrin
Journal:  Anal Biochem       Date:  1979-09-15       Impact factor: 3.365

2.  Nucleotide sequence of the papA gene encoding the Pap pilus subunit of human uropathogenic Escherichia coli.

Authors:  M Båga; S Normark; J Hardy; P O'Hanley; D Lark; O Olsson; G Schoolnik; S Falkow
Journal:  J Bacteriol       Date:  1984-01       Impact factor: 3.490

3.  Haemolysin contributes to virulence of extra-intestinal E. coli infections.

Authors:  R A Welch; E P Dellinger; B Minshew; S Falkow
Journal:  Nature       Date:  1981-12-17       Impact factor: 49.962

4.  Cytotoxic activity of partially purified Escherichia coli alpha haemolysin.

Authors:  S J Cavalieri; I S Snyder
Journal:  J Med Microbiol       Date:  1982-02       Impact factor: 2.472

5.  Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin.

Authors:  L Hagberg; I Engberg; R Freter; J Lam; S Olling; C Svanborg Edén
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

6.  Gene clusters governing the production of hemolysin and mannose-resistant hemagglutination are closely linked in Escherichia coli serotype O4 and O6 isolates from urinary tract infections.

Authors:  D Low; V David; D Lark; G Schoolnik; S Falkow
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

7.  In vivo function of hemolysin in the nephropathogenicity of Escherichia coli.

Authors:  C Waalwijk; D M MacLaren; J de Graaff
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

8.  Cloned hemolysin genes from Escherichia coli that cause urinary tract infection determine different levels of toxicity in mice.

Authors:  J Hacker; C Hughes; H Hof; W Goebel
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

9.  The role of alpha haemolysin in the virulence of Escherichia coli for mice.

Authors:  M A Linggood; P L Ingram
Journal:  J Med Microbiol       Date:  1982-02       Impact factor: 2.472

10.  Effects of a single hit from the alpha hemolysin produced by Escherichia coli on the morphology of sheep erythrocytes.

Authors:  S E Jorgensen; R F Hammer; G K Wu
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

View more
  42 in total

Review 1.  Host-pathogen interactions in urinary tract infection.

Authors:  Greta R Nielubowicz; Harry L T Mobley
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

2.  Phylogenetic and pathotypic comparison of concurrent urine and rectal Escherichia coli isolates from men with febrile urinary tract infection.

Authors:  James R Johnson; Flemming Scheutz; Peter Ulleryd; Michael A Kuskowski; Timothy T O'Bryan; Torsten Sandberg
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Stacy A Genagon; Ulrike MacDonald; John J Cope; Bruce A Davidson; Brian Johnston; James R Johnson
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

4.  Antibodies against hemolysin and cytotoxic necrotizing factor type 1 (CNF1) reduce bladder inflammation in a mouse model of urinary tract infection with toxigenic uropathogenic Escherichia coli.

Authors:  Mark A Smith; Rebecca A Weingarten; Lisa M Russo; Christy L Ventura; Alison D O'Brien
Journal:  Infect Immun       Date:  2015-02-09       Impact factor: 3.441

5.  Inactivation of host Akt/protein kinase B signaling by bacterial pore-forming toxins.

Authors:  Travis J Wiles; Bijaya K Dhakal; Danelle S Eto; Matthew A Mulvey
Journal:  Mol Biol Cell       Date:  2008-01-30       Impact factor: 4.138

6.  Insulin and the phosphatidylinositol 3-kinase signaling pathway regulate Ribonuclease 7 expression in the human urinary tract.

Authors:  Tad E Eichler; Brian Becknell; Robert S Easterling; Susan E Ingraham; Daniel M Cohen; Andrew L Schwaderer; David S Hains; Birong Li; Ariel Cohen; Jackie Metheny; Susheela Tridandapani; John David Spencer
Journal:  Kidney Int       Date:  2016-07-09       Impact factor: 10.612

7.  The UPEC pore-forming toxin α-hemolysin triggers proteolysis of host proteins to disrupt cell adhesion, inflammatory, and survival pathways.

Authors:  Bijaya K Dhakal; Matthew A Mulvey
Journal:  Cell Host Microbe       Date:  2012-01-19       Impact factor: 21.023

8.  Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli.

Authors:  Danilo Gomes Moriel; Isabella Bertoldi; Angela Spagnuolo; Sara Marchi; Roberto Rosini; Barbara Nesta; Ilaria Pastorello; Vanja A Mariani Corea; Giulia Torricelli; Elena Cartocci; Silvana Savino; Maria Scarselli; Ulrich Dobrindt; Jörg Hacker; Hervé Tettelin; Luke J Tallon; Steven Sullivan; Lothar H Wieler; Christa Ewers; Derek Pickard; Gordon Dougan; Maria Rita Fontana; Rino Rappuoli; Mariagrazia Pizza; Laura Serino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

9.  In vivo gene expression analysis identifies genes required for enhanced colonization of the mouse urinary tract by uropathogenic Escherichia coli strain CFT073 dsdA.

Authors:  Brian J Haugen; Shahaireen Pellett; Peter Redford; Holly L Hamilton; Paula L Roesch; Rodney A Welch
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

10.  Mucosal immunization with iron receptor antigens protects against urinary tract infection.

Authors:  Christopher J Alteri; Erin C Hagan; Kelsey E Sivick; Sara N Smith; Harry L T Mobley
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.